Table 1. Baseline characteristics of the study population.
| Total (n = 131) | |
|---|---|
| Male (n, %) | 95 (72.5%) |
| Age (year) | 39 ± 10 |
| HBeAg positive, n (%) | 87 (66.4%) |
| HBV DNA (log10 copies/ml) | 5.6 (3.5–7.5) |
| ALT (IU/L) | 47 (29–70) |
| AST (IU/L) | 30 (24–37) |
| GGT (IU/L) | 45 (16–57) |
| Platelet count (109/L) | 182 ± 61 |
| GPR | 0.40 (0.17–0.77) |
| APRI | 0.44 (0.32–0.69) |
| FIB-4 | 0.98 (0.68–1.43) |
| Median BMI (kg/m2) | 26 (23–28) |
| METAVIR Inflammation stage (A0/A1/A2/A3) | 11 (8.4%)/47 (35.9%)/58 (44.3%)/15 (11.5%) |
| METAVIR Fibrosis stage (F0/F1/F2/F3/F4) | 13 (9.9%)/77 (58.8%)/21 (16.0%)/10 (7.6%)/10 (7.6%) |
| Hepatic steatosis stage (G1/G2/G3/G4) | 65 (49.6%)/41 (31.3%)/15 (11.5%)/10 (7.6%) |
HBeAg, hepatitis B e antigen; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl transpeptidase; GPR, GGT to platelet ratio index; APRI, AST to platelet ratio index; FIB-4, fibrosis index based on the 4 factors; BMI, body mass index.